



Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis

| | |
|------------------------------|--|
| 著者 | Fujimoto Yasuyuki, Azuma Yasu-Taka, Matsuo Yukiko, Kuwamura Mitsuru, Kuramoto Nobuyuki, Miki Mariko, Azuma Naoki, Teramoto Midori, Nishiyama Kazuhiro, Izawa Takeshi, Nakajima Hidemitsu, Takeuchi Tadayoshi |
| journal or publication title | Naunyn-Schmiedeberg's Archives of Pharmacology |
| volume | 390 |
| number | 3 |
| page range | 261-268 |
| year | 2017-03 |
| 権利 | This is a post-peer-review, pre-copyedit version of an article published in Naunyn-Schmiedeberg's Archives of Pharmacology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00210-016-1329-0 . |
| URL | http://hdl.handle.net/10466/15734 |

doi: 10.1007/s00210-016-1329-0

[Click here to view linked References](#)

Azuma YT et al.

1
2 **Interleukin-19 contributes as a protective factor in experimental**
3
4
5 **Th2-mediated colitis**
6

7
8
9
10 Yasuyuki Fujimoto¹ · Yasu-Taka Azuma^{*,1} · Yukiko Matsuo¹ · Mitsuru
11
12 Kuwamura² · Nobuyuki Kuramoto³ · Mariko Miki¹ · Naoki Azuma¹ · Midori
13
14 Teramoto¹ · Kazuhiro Nishiyama¹ · Takeshi Izawa² · Hidemitsu Nakajima¹ ·
15
16
17
18
19 Tadayoshi Takeuchi¹
20
21
22
23
24

25 ¹*Laboratory of Veterinary Pharmacology, Division of Veterinary Science,*
26
27
28 *Osaka Prefecture University Graduate School of Life and Environmental*
29
30 *Science, Izumisano, Osaka, Japan*
31

32
33
34 ²*Laboratory of Veterinary Pathology, Division of Veterinary Science, Osaka*
35
36
37 *Prefecture University Graduate School of Life and Environmental Science,*
38
39
40 *Izumisano, Osaka, Japan*
41

42
43 ³*Laboratory of Molecular Pharmacology, Setsunan University Faculty of*
44
45
46 *Pharmaceutical Sciences, Hirakata, Osaka 573-0101, Japan*
47
48

49
50
51
52 *Corresponding author at: Laboratory of Veterinary Pharmacology, Division
53
54
55 of Veterinary Science, Osaka Prefecture University Graduate School of Life
56
57
58 and Environmental Science, 1-58 Rinku-ohraikita, Izumisano, Osaka
59
60

1
2 598-8531, Japan. Tel/Fax: +81-(0)72-463-5264.
3

4
5 E-mail: azuma@vet.osakafu-u.ac.jp (Y.T. Azuma).
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Inflammatory bowel disease results from chronic dysregulation of the mucosal immune system and aberrant activation of both the innate and adaptive immune responses. IL-19 is a member of the IL-10 family, and IL-10 plays important role in inflammatory bowel disease. We have previously shown that IL-19 knockout mice are more susceptible to innate-mediated colitis. Next, we ask whether IL-19 contributes to T cells-mediated colitis. Here, we investigated the role of IL-19 in a mouse model of Th2 cell-mediated colitis. Inflammatory responses in IL-19-deficient mice were assessed using a Th2-mediated colitis induced by oxazolone. The colitis was evaluated by analyzing body weight loss and histology of the colon. Lymph node cells were cultured *in vitro* to determine cytokine production. IL-19 knockout mice exacerbated oxazolone-induced colitis by stimulating the transport of inflammatory cells into the colon, and by increasing IgE production and the number of circulating eosinophil. The exacerbation of oxazolone-induced colonic inflammation following IL-19 knockout mice was accompanied by increased production of IL-4 and IL-9, but no changes in the expression of IL-5 and IL-13 in lymph node cells. IL-19 plays an anti-inflammatory role in the Th2-mediated colitis model, suggesting that IL-19 may represent potential

1
2 therapeutic target for reducing colonic inflammation.
3
4
5
6

7
8 **Key Words**
9

10 IL-19, anti-inflammatory cytokine, inflammatory bowel disease
11
12
13
14
15

16
17 **Abbreviations**
18
19
20

21
22 CD Crohn's disease
23
24

25 DSS dextran sulfate sodium
26
27

28 HE hematoxylin and eosin
29
30

31 IBDs inflammatory bowel diseases
32
33

34 IFN interferon
35
36

37 KO IL-19-knockout
38
39

40 MPO myeloperoxidase
41
42

43 UC ulcerative colitis
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

IL-19 was originally found by sequence homology to IL-10 (Gallagher et al., 2000), and is a member of the IL-10 family, which also includes IL-20, IL-22, IL-24, IL-26, IL-28A, IL-28B, and IL-29 (Sabat et al., 2007). Our previous studies showed that IL-19-knockout (KO) mice are more susceptible to experimental acute colitis induced by dextran sulfate sodium (DSS), and this increased susceptibility is correlated with the accumulation of macrophages and the increased production of interferon (IFN)- γ , IL-1 β , IL-6, IL-12, TNF- α , and CXCL1 (Azuma et al., 2010a).

DSS-induced colitis is a well-characterized model of colonic inflammation. The adaptive immune system obviously does not play a major part in DSS-induced colitis model, because T- and B-cell-deficient mice also develop severe colonic inflammation in this model (Dieleman et al., 1994). Clinically, Ulcerative colitis (UC) and Crohn's disease (CD) are two of the most common types of inflammatory bowel diseases (IBDs) and are characterized by dysregulated intestinal inflammation and mucosal tissue damage in parts of the gastrointestinal tract (Tong et al., 2013). CD is characterized by transmural and discontinuous inflammation, which is associated with a type-1 response mainly driven by IL-12 and IFN- γ

1
2 (Monteleone et al., 2005). In contrast, UC involves the superficial mucosal
3
4 and submucosal layers of the colon and is driven by type-2 cytokines, such as
5
6
7 IL-4, IL-5, and IL-13 (Tanaka et al., 2010). However, little is known about the
8
9 exact immunological role of IL-19 in the regulation of IBD such as T-cell
10
11 mediated colonic inflammation.
12
13
14
15

16
17 To determine the potential role of IL-19 in IBD, we previously
18
19 examined the role of IL-19 in the 2,4,6-trinitrobenzene sulfonic acid
20
21 (TNBS)-induced colitis model which shows a clear type-1 phenotype (Kitani
22
23 et al., 2000). We demonstrated that IL-19-KO mice aggravated TNBS-induced
24
25 colitis (Matsuo et al., 2015). Since TNBS-induced colitis resembles the
26
27 symptom seen in CD, the exact immunological role of IL-19 in the regulation
28
29 of UC remains still unclear. In this study, we investigated the role of IL-19 in
30
31 oxazolone-induced colitis which is useful for the study of the type-2
32
33 inflammatory response and resembles the symptom seen in UC (Heller et al.,
34
35 2002; Boirivant et al., 1998).
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Materials and Methods**

50 **Mice**

51
52 We constructed targeting vectors for the IL-19 gene and used them to generate
53
54
55 IL-19-KO mice. C57BL/6-IL-19 mice were backcrossed onto the Balb/c
56
57
58
59
60
61
62
63
64
65

1
2 genetic background for at least 10 generations. Balb/c-IL-19 heterozygous
3
4
5 mice were intercrossed to generate mutant and control mice. Age-matched
6
7
8 mice (10–15 weeks old) were used in all experiments. All procedures used in
9
10
11 this study complied with institutional policies of the Osaka Prefecture
12
13
14 University Animal Care and Use Committee.
15

16 17 18 19 Oxazolone-induced colitis

20
21
22 To presensitize mice, a 2 × 2 cm field of the abdominal skin was shaved, and
23
24
25 150 µL of a 4% (w/v) solution of oxazolone in 100% ethanol was applied.
26
27
28 Seven days after presensitization, colitis was induced by intrarectal
29
30
31 administration with 100 µL of 3% of oxazolone in 50% ethanol using a plastic
32
33
34 catheter. Control mice were administered a 50% ethanol solution without
35
36
37 oxazolone using the same technique. Body weights were monitored daily.
38
39
40
41
42

43 RNA isolation and quantitative real-time reverse transcription polymerase 44 45 46 chain reaction

47
48
49 Total RNA was isolated from the distal colon as previously described (Azuma
50
51
52 et al., [2010b](#)), with minor modifications. RNA was used to synthesize
53
54
55 complementary cDNA using SuperScript Reverse Transcriptase (Roche,
56
57
58 Madison, WI, USA). The primers used for amplification of IL-19 were as
59
60
61
62
63
64
65

1 follows: 5'-ATGAAGACACAGTGCGCGTC-3' and
2
3
4
5 5'-GTGTCAGGCTGCAGGAG-3'. mRNA expression levels were quantified
6
7 using real-time PCR analysis based on the intercalation of SYBR Green
8
9
10 (Toyobo, Osaka, Japan). The amplification of *HPRT* mRNA was used as an
11
12 endogenous control to account for differences in the amount and quality of
13
14 RNA added to each reaction.
15
16
17
18
19
20
21

22 Histology

23
24
25 The distal colon was fixed with 10% neutral buffered formalin and embedded
26
27 in paraffin. Sections were stained with hematoxylin and eosin (HE). The
28
29 severity of intestinal inflammation was graded using a previously described
30
31 system for colitis from 0 to 4 as follows: 0, no leukocyte infiltration; 1, low
32
33 level of leukocytic infiltration; 2, moderate level of leukocytic infiltration; 3,
34
35 high level of leukocytic infiltration, high vascular density, thickening of the
36
37 colon wall; and 4, transmural infiltration, loss of goblet cells, high vascular
38
39 density, thickening of the colon wall (Fuss et al., 1999). All sections were
40
41 scored in a blinded fashion by a pathologist.
42
43
44
45
46
47
48
49
50
51

52 Myeloperoxidase (MPO) activity in the colon

1
2 Neutrophil infiltration into the colon was quantified by measurement of MPO
3
4 activity. The distal colon was homogenized in PBS containing Complete
5
6 Lysis-M (Roche). Homogenized samples were placed on a rotary shaker at 300
7
8 rpm on ice for 30 min and centrifuged at $12,000 \times g$ for 10 min. Supernatants
9
10 were then collected, and protein concentrations were quantified and adjusted
11
12 to 0.9 mg/mL. MPO activity was determined using an EnzChek MPO Activity
13
14 Assay Kit (Life Technologies, Palo Alto, CA, USA) according to the
15
16 manufacturer's instructions.
17
18
19
20
21
22
23
24
25
26
27

28 Immunofluorescence staining

29
30
31 The distal colon was fixed with 4% paraformaldehyde. Frozen sections (5 μm
32
33 thick) were prepared for immunofluorescence staining as previously described
34
35 (Azuma et al., [2008](#)), with minor modifications. Macrophages were detected
36
37 using rat anti-mouse F4/80 monoclonal antibodies conjugated to Alexa Fluor
38
39 647 (CI:A3-1; AbD Serotec). Neutrophils were detected using rat anti-mouse
40
41 Gr-1 monoclonal antibodies conjugated to Alexa Fluor 488 (RB6-8C5; AbD
42
43 Serotec). Confocal images were obtained under a laser-scanning microscope
44
45 (C1si; Nikon Corporation, Tokyo, Japan).
46
47
48
49
50
51
52
53
54
55
56
57

58 IgE ELISA

1 Serum IgE levels were measured by ELISA (Koma Biotech, Seoul, Korea)
2
3
4
5 according to the manufacturer's instructions.
6
7
8
9

10 Differential white blood cell counts

11
12 Blood smears slides were stained with Giemsa (Wako, Osaka, Japan).
13
14
15

16 Differential cell counts were determined for 2000 cells per slide under oil at
17
18
19 60× magnification. During cell counting, the researcher was blinded to the
20
21
22 experimental treatment.
23
24
25
26
27

28 Eosinophil staining

29
30 Eosinophil infiltration into the distal colon was stained by Eosinophil Stain
31
32 Kit (ScyTek Laboratories, Inc., UT, USA). Simultaneously, acidic
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66 Cell isolation and cytokine production

67
68 Mesenteric lymph nodes were isolated. Lymph node cells were isolated by
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

1
2 Biotec, Bergisch Gladbach, Germany). Simultaneously, we collected and used
3
4 lymph node cells by negative selection with CD4 microbeads. CD4⁺ T-cells
5
6 from lymph node were stimulated with BioCoat anti-mouse CD3 T-cell
7
8 activation plates (BD, Franklin Lakes, NJ, USA), whereas lymph node cells by
9
10 negative selection with CD4 MicroBeads were cultured with normal plates.
11
12 After 48 h of culture, cytokine concentrations were determined in the culture
13
14 supernatants using enzyme-linked immunosorbent assays (ELISAs;
15
16 eBioscience, San Diego, CA, USA) and multiplex assays (Bio-Rad, Hercules,
17
18 CA, USA) according to the manufacturer's instructions.
19
20
21
22
23
24
25
26
27
28
29
30

31 Statistical analysis

32
33 Results are expressed as the mean \pm standard error of the mean (SEM).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Histological scores were statistically analyzed using the Mann-Whitney U test. Differences in parametric data were evaluated using Student's t tests. Differences with *P* values of less than 0.05 were considered significant.

66 Results

67 Increased susceptibility of IL-19-KO mice to oxazolone-induced colitis

68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

We initially investigated the susceptibility of IL-19-KO mice to the development of oxazolone-induced colitis by analyzing body weight loss and

1 histology of the distal colon. IL-19-KO mice showed severe weight loss
2 compared with WT control mice from day 1 to day 2 (Fig. 1A). As shown in
3
4
5
6
7
8 Figure 1B, the administration of oxazolone to WT mice induced the expression
9
10 of *IL-19* mRNA in the distal colon 2 days after oxazolone administration.
11
12 Simultaneously, the administration of oxazolone to IL-19-KO mice induced no
13
14 expression of *IL-19* mRNA on day 2 (data now shown). Histological analysis
15
16 revealed that the distal colon in IL-19-KO mice exhibited increased numbers
17
18 of infiltrating cells and a general loss of tissue architecture 2 days after
19
20 oxazolone administration (Fig. 1C). The severity of colitis, as represented by
21
22 the histological score, was significantly increased in IL-19-KO mice compared
23
24 with WT mice (Fig. 1C).
25
26
27
28
29
30
31
32
33

34 In IL-19-KO mice, oxazolone treatment increased colonic MPO activity
35
36 (Fig. 2A), consistent with a marked increase in neutrophil infiltration as
37
38 evaluated using anti-Gr-1 antibodies (Fig. 2B). Interestingly, macrophage
39
40 infiltration (evaluated using anti-F4/80 antibodies) was also highly increased
41
42 in IL-19-KO mice with oxazolone-induced colitis (Fig. 2B).
43
44
45
46
47
48

49 IL-4 induces type-2 inflammatory responses, thereby stimulating
50
51 production of IL-13, B-cell-dependent production of serum IgE and
52
53 recruitment of eosinophils in mice with oxazolone-induced colitis (Hoving et
54
55 al., 2012). Therefore, we assessed serum IgE levels and blood eosinophil
56
57
58
59
60
61
62
63
64
65

1
2 levels in mice with oxazolone-induced colitis. Interestingly, circulating IgE
3
4
5 levels were significantly elevated in IL-19-KO mice in comparison with WT
6
7
8 mice (Fig. 2C). The number of circulating eosinophils was also significantly
9
10
11 elevated in IL-19-KO mice as compared with WT mice (Fig. 2D upper panel).

12
13 To estimate the eosinophil infiltration of IL-19-KO tissue preparations in the
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

To estimate the eosinophil infiltration of IL-19-KO tissue preparations in the
distal colon, we used Eosinophil Stain Kit. Administration of oxazolone to
IL-19-KO mice showed marked eosinophil infiltrations as indicated red color
(Fig. 2D lower panels). However, WT showed little eosinophil infiltrations.

Collectively, these results showed that IL-19 deficiency exacerbated
oxazolone-induced colitis by facilitating the transport of inflammatory cells
into the colon.

Expression of inflammatory cytokines in the colons of mice with
oxazolone-induced colitis

To investigate the potential inflammatory mediators that may be altered by
IL-19 during oxazolone-induced colitis, we analyzed the expression of various
inflammatory mediators (i.e., *IL-1 β* , *IL-4*, *IL-6*, *TNF- α* , and *IL-10*) by
real-time PCR. Interestingly, administration of oxazolone to IL-19-KO mice
increased the expression of *IL-1 β* and *IL-4* mRNA in the distal colon (Fig. 3).

In contrast, IL-19-KO mice decreased the expression of *IL-10* mRNA.

1
2 However, the levels of *IL-6* and *TNF- α* were similar in WT and IL-19-KO
3
4 mice. These results suggested that IL-19 played an important role in the
5
6 **IL-4-mediated** inflammatory responses in mice with oxazolone-induced
7
8 colitis.
9
10

11
12
13
14
15
16 Altered cytokine production in lymph node cells from IL-19-KO mice with
17
18 oxazolone-induced colitis
19
20

21
22 Because the oxazolone-induced colitis model has been associated with
23
24 increases in Th2 responses (Heller et al., 2002; Boirivant et al., 1998), we
25
26 examined the levels of several types of cytokines in lymph node cells. As
27
28 shown in **Figure 4A**, CD4⁺ T-cells isolated from lymph node of IL-19-KO mice
29
30 with oxazolone-induced colitis produced elevated amounts of IL-2, IL-4, IL-9
31
32 and CCL5 upon stimulation with anti-CD3 and anti-CD28 antibodies *in vitro*.
33
34

35
36
37
38
39
40 **However, there are no marked changes in the amounts of IL-5, IL-13 (Fig. 4A)**
41
42 **and IL-17 (data not shown)**. These results suggested that IL-19 controlled Th2
43
44 cytokine IL-4. At the same time, we measured the production of several
45
46 cytokines in lymph node cells by negative selection with CD4⁺. As shown in
47
48 **Figure 4B**, IL-19-KO mice produced high levels of IL-12, G-CSF and CXCL1,
49
50 **but not TNF- α , IL-1 β and IL-6**, suggesting that the production of **these**
51
52 cytokines is controlled by IL-19.
53
54
55
56
57
58
59
60
61
62

Discussion

In this study, our experiments highlighted several novel aspects of the anti-inflammatory effects of IL-19 in Th2-mediated colitis *in vivo*. We found that the exacerbation of oxazolone-induced colitis by IL-19 deficiency was accompanied by increased production of IL-4 and IL-9 without increased production of IL-5 and IL-13. The oxazolone-induced colitis and UC include characteristic ulcers of the colon, which form through an IL-4-driven, Th2-mediated response to oxazolone (Heller et al., 2002; Boirivant et al., 1998). In addition, IL-4, IL-5, and IL-13 are upregulated in keratin 8-KO mice, which develop chronic spontaneous Th2-mediated colitis (Habtezion et al., 2005). IL-4 and IL-5 are correlated with the clinical and histological severity of colitis in UC patients (Inoue et al., 1999). IL-13 was found to be upregulated in UC patients and linked to an impaired epithelial barrier function in the gut (Heller et al., 2005). **Indeed, IL-5 and IL-13 as well as IL-4 have important roles in colonic inflammation. Why did IL-19-KO mice show increased production of IL-4, but not IL-5 and IL-13?** Although IL-4 and IL-13 are structurally analogous and share functional receptors, their function is quite different. IL-4 acts mainly as a regulatory cytokine and IL-13 acts as

1
2 an effector cytokine. IL-5 plays a key role in eosinophil proliferation,
3
4 differentiation, maturation, migration to tissue sites and **survival**
5
6 (Sitkauskiene et al., 2004). IL-4 was mainly produced by Th2, and Th2
7
8 produced IL-5 and IL-13. IL-5 and IL-13 were also produced by innate
9
10 lymphoid cells and invariant natural killer T cells. IL-4 and IL-5 promote the
11
12 clonal expansion and maturation of B cells and induces the IgM/IgE switch.
13
14 Released IgE activate mast cells to secrete IL-4, IL-5 and IL-13. In contrast, a
15
16 recent study reported that IL-9 plays an important role in driving UC by
17
18 regulating intestinal epithelial cells and that IL-9 represents a promising
19
20 target for the treatment of chronic colitis (Gerlach et al., 2014). Thus, it is
21
22 possible that IL-19 regulates IL-4 and IL-9 production, but not IL-5 and IL-13
23
24 production, because all of these cytokines are significant pathological factors
25
26 in oxazolone-induced colitis (Heller et al., 2002; Boirivant et al., 1998). **In**
27
28 **line with these previous findings, our data suggest that IL-19 plays important**
29
30 **role in the gut by regulating Th2 cells to produce IL-4, but not innate**
31
32 **lymphoid cells and invariant natural killer T cells to produce IL-5 and IL-13.**
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48
49 It is not surprising to find that IL-2 was increased in IL-19-KO
50
51 compared to WT. IL-2 plays a critical role in the polarization of naive CD4 T
52
53 cells to the Th2 phenotype as well as Th1 clearly needs IL-2 (Cote-Sierra et
54
55 al., 2004). CCL5 is a chemotactic agent for T cells, eosinophils, and basophils
56
57
58
59
60
61
62
63
64
65

1 and plays an active role in recruiting leukocytes to sites of inflammation.
2
3
4 CCL5 does not play the survival for eosinophils although IL-3, IL-5 and
5
6
7 GM-CSF play the survival for eosinophils. We found that IL-19-KO showed
8
9
10 increased production of CCL5 though no alteration on the production of IL-3,
11
12
13 IL-5 and GM-CSF (Fig. 4A and data not shown), suggesting that IL-19 control
14
15
16 migration and infiltration to the tissue of eosinophils, but not proliferation
17
18
19 and survival for eosinophils.
20
21

22 IL-10 is a well-known anti-inflammatory and immunosuppressive
23
24
25 cytokine. Anti-inflammatory effect of IL-19 is reminiscent of the widely
26
27
28 accepted regulation of IL-10. There is the possibility that altered production
29
30
31 of cytokines in IL-19-KO was due to downregulation of IL-10.
32
33

34 Th17 is responsible for the IL-17 production, a key pro-inflammatory
35
36
37 cytokine that is increased in IBD (Zhu et al., 2015). There is the possibility
38
39
40 that altered production of cytokines in IL-19-KO was due to upregulation of
41
42
43 IL-17. However, both WT and IL-19-KO secreted equivalent amounts of IL-17
44
45
46 (data not shown), suggesting that IL-17 is not likely to mediate the
47
48
49 suppressive effect of IL-19.
50
51

52 Interestingly, we observed increased levels of IL-12, G-CSF and
53
54
55 CXCL1 in IL-19-KO mice with oxazolone-induced colitis. G-CSF
56
57
58 stimulates the survival, proliferation, differentiation, and functions of
59
60
61

1
2 neutrophil precursors and mature neutrophils and can induce the production of
3
4
5 granulocytes in the bone marrow. CXCL1 has neutrophil chemoattractant
6
7
8 activity and has been shown to function by signaling through the chemokine
9
10
11 receptor CXCR2, which is expressed on the surface of neutrophils. In a
12
13
14 previous study, researchers found that the colons of mice with
15
16
17 oxazolone-induced are flooded with inflammatory cells, including Gr-1⁺
18
19
20 neutrophils, $\gamma\delta$ T cells, eosinophils, NKT cells, and CD4⁺ T-cells (Camelo et
21
22
23 al., 2012). Consistent with previous result, we found here that IL-19-KO mice
24
25
26 exhibited increased Gr-1⁺ neutrophils and eosinophils, supporting the role of
27
28
29 IL-19 in mediating intestinal inflammation. IL-12 is a well-known Th1
30
31
32 cytokine. In addition, IL-12 mediates enhancement of the cytotoxic activity of
33
34
35 NK cells and CD8⁺ cytotoxic T-cells. Thus, it is possible that IL-19 may
36
37
38 regulate NK cells and CD8⁺ cytotoxic T-cells in oxazolone-induced colitis.
39

40
41 It is well known that pro-inflammatory cytokines play an important role
42
43
44 in inflammation of the intestinal mucosa. For instance, IL-6, IL-1 β , and
45
46
47 TNF- α have been shown to play pivotal roles in the pathogenesis of IBD
48
49
50 (Fiocchi, 1998; Bouma and Strober, 2003). Both IL-6-deficient mice and
51
52
53 caspase-1 (IL-1 β converting enzyme)-deficient mice have been shown to have
54
55
56 less severe colitis induced by DSS, suggesting that IL-6 and IL-1 β both play a
57
58
59 role in promoting T-cell-independent acute colitis (Siegmund et al., 2001;
60
61
62
63
64
65

1
2 Naito et al., 2004). In contrast, TNF- α -deficient mice have been shown to be
3
4
5 more susceptible to DSS-induced colitis (Naito et al., 2003), whereas a low
6
7
8 dose TNF- α monoclonal antibody treatment protected against chronic colitis
9
10
11 (Kojouharoff et al., 1997). In our study, lymph node cells showed a similar
12
13
14 production of IL-6, IL-1 β and TNF- α between WT and IL-19-KO.
15
16
17 Interestingly, we also found that real-time RT-PCR analysis of the distal
18
19
20 colons of mice showed increased expression of IL-1 β , but not IL-6 and
21
22
23 TNF- α , in IL-19-KO compared to WT. It is likely that non-immune cells in the
24
25
26 gut tissue produced IL-1 β in IL-19-KO with oxazolone-induced colitis. These
27
28
29 results indicate that IL-19 may play as anti-inflammatory effector by acting
30
31
32 both immune cell and non-immune cell, regardless of the mechanism.
33

34
35 In a previous study, we showed that DSS-induced colitis is exacerbated
36
37
38 in IL-19-KO mice (Azuma et al., 2010a). The increased severity of colonic
39
40
41 inflammation following genetic ablation of IL-19 was accompanied by
42
43
44 increased production of many inflammatory cytokines, including IFN- γ ,
45
46
47 IL-1 β , IL-6, IL-12, TNF- α , and CXCL1, several of which have been implicated
48
49
50 in the pathogenesis of DSS-induced colitis. In contrast, CD4⁺ T-cells have
51
52
53 been shown to play a central role in IBD. We showed that IL-19 deficiency
54
55
56 aggravated TNBS-induced colitis. Additionally, the exacerbation of
57
58
59 TNBS-induced colonic inflammation following genetic ablation of IL-19 was
60
61
62
63
64
65

1
2 accompanied by increased production of IFN- γ , IL-12, IL-17, IL-22 and IL-33
3
4 (Matsuo et al., 2015). IL-19 can have anti-inflammatory roles in the gut,
5
6
7 regardless the type of colonic inflammation. In type-1 responses, such as in
8
9
10 DSS and TNBS-induced colitis, we revealed that IL-19 clearly plays
11
12 anti-inflammatory role. In type-2 responses, our present study provides solid
13
14 evidence for the immunopathological relevance of IL-19 as an
15
16
17 anti-inflammatory cytokine in colonic inflammation. Consistent with our data,
18
19
20 recent studies have reported that IL-19 is impaired in patients with active UC
21
22
23 (Fonseca-Camarillo et al., 2014). Our data add a new key player as colonic
24
25
26 inflammation, showing that IL-19 act as potent anti-inflammatory cytokine.
27
28
29
30
31
32
33

34 **Acknowledgments** This work was supported by Grants-in-Aid for Young
35
36
37 Scientists (B) 20780209 (Y.T.A.) and 23780300 (Y.T.A.), and was supported
38
39
40 by Grant-in-Aid for Scientific Research (B) 25292174 (Y.T.A.).
41
42
43
44
45

46 **Conflict of interest** The authors declare that they have no conflicts of
47
48
49 interest to declare.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 **References**
3
4
5
6

- 7
8 Azuma YT, Hagi K, Shintani N, Kuwamura M, Nakajima H, Hashimoto H,
9
10 Baba A, Takeuchi T (2008) PACAP provides colonic protection against
11
12 dextran sodium sulfate induced colitis. *J Cell Physiol* 216:111-119
13
14
15
16 Azuma YT, Matsuo Y, Kuwamura M, Yancopoulos GD, Valenzuela DM,
17
18
19 Murphy AJ, Nakajima H, Karow M, Takeuchi T (2010a) Interleukin-19
20
21
22 protects mice from innate-mediated colonic inflammation. *Inflamm*
23
24
25
26 *Bowel Dis* 16:1017-1028
27
28 Azuma YT, Nishiyama K, Matsuo Y, Kuwamura M, Morioka A, Nakajima H,
29
30
31 Takeuchi T (2010b) PPAR α contributes to colonic protection in mice with
32
33
34
35
36
37
38 Boirivant M, Fuss IJ, Chu A, Strober W (1998) Oxazolone colitis: a murine
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Bouma G, Strober W (2003) The immunological and genetic basis of
inflammatory bowel disease. *Nat Rev Immunol* 3:521-533
- Camelo A, Barlow JL, Drynan LF, Neill DR, Ballantyne SJ, Wong SH, Pannell
R, Gao W, Wrigley K, Sprenkle J, McKenzie AN (2012) Blocking IL-25
signalling protects against gut inflammation in a type-2 model of colitis

1
2 by suppressing nuocyte and NKT derived IL-13. J Gastroenterol
3
4
5 47:1198-1211
6

7 Cote-Sierra J, Foucras G, Guo L, Chiodetti L, Young HA, Hu-Li J, Paul
8
9
10 WE (2004) Interleukin 2 plays a central role in Th2 differentiation. Proc
11
12
13 Natl Acad Sci USA 101:3880-3885
14
15

16 Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO
17
18
19 (1994) Dextran sulfate sodium-induced colitis occurs in severe combined
20
21
22 immunodeficient mice. Gastroenterology 107:1643-1652
23
24

25 Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis.
26
27
28 Gastroenterology 115:182-205
29
30

31 Fonseca-Camarillo G, Furuzawa-Carballeda J, Granados J,
32
33
34 Yamamoto-Furusho JK (2014) Expression of interleukin (IL)-19 and
35
36
37 IL-24 in inflammatory bowel disease patients: a cross-sectional study.
38
39
40 Clin Exp Immunol 177:64-75
41
42

43 Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W (1999)
44
45
46 Anti-interleukin 12 treatment regulates apoptosis of Th1 cells in
47
48
49 experimental colitis in mice. Gastroenterology 117:1078-1088
50
51

52 Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV,
53
54
55 Peat JD, Vazquez N, Pestka S, Donnelly RP, Kotenko SV (2000) Cloning,
56
57
58 expression and initial characterization of interleukin-19 (IL-19), a novel
59
60
61

1
2 homologue of human interleukin-10 (IL-10). *Genes Immun* 1:442-450
3

4
5 Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, Lehr HA,
6
7 Wirtz S, Vieth M, Waisman A, Rosenbauer F, McKenzie AN, Weigmann
8
9 B, Neurath MF (2014) TH9 cells that express the transcription factor
10
11 PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in
12
13 PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in
14
15 intestinal epithelial cells. *Nat Immunol* 15:676-686
16
17
18

19
20 Habtezion A, Toivola DM, Butcher EC, Omary MB (2005) Keratin-8-deficient
21
22 mice develop chronic spontaneous Th2 colitis amenable to antibiotic
23
24 treatment. *J Cell Sci* 118:1971-1980
25
26

27
28 Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz
29
30 J, Gitter AH, Bürgel N, Fromm M, Zeitz M, Fuss I, Strober W, Schulzke
31
32 JD (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative
33
34 colitis that affects epithelial tight junctions, apoptosis, and cell
35
36 restitution. *Gastroenterology* 129:550-564
37
38
39

40
41 Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W (2002)
42
43 Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is
44
45 mediated by IL-13-producing NK-T cells. *Immunity* 17:629-638
46
47
48

49
50 Hoving JC, Kirstein F, Nieuwenhuizen NE, Fick LC, Hobeika E, Reth M,
51
52 Brombacher F (2012) B cells that produce immunoglobulin E mediate
53
54 colitis in BALB/c mice. *Gastroenterology* 142:96-108
55
56
57
58
59
60

1
2 Inoue S, Matsumoto T, Iida M, Mizuno M, Kuroki F, Hoshika K, Shimizu M
3
4
5 (1999) Characterization of cytokine expression in the rectal mucosa of
6
7
8 ulcerative colitis: correlation with disease activity. *Am J Gastroenterol*
9
10
11 94:2441-2446

12
13 Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, Strober W (2000).
14
15
16 Treatment of experimental (trinitrobenzene sulfonic acid) colitis by
17
18
19 intranasal administration of transforming growth factor (TGF)-beta1
20
21
22 plasmid: TGF-beta1-mediated suppression of T helper cell type 1
23
24
25 response occurs by interleukin (IL)-10 induction and IL-12 receptor
26
27
28 beta2 chain downregulation. *J Exp Med* 192:41-52

29
30
31 Kojouharoff G, Hans W, Obermeier F, Männel DN, Andus T, Schölmerich J,
32
33
34 Gross V, Falk W (1997) Neutralization of tumour necrosis factor (TNF)
35
36
37 but not of IL-1 reduces inflammation in chronic dextran sulphate
38
39
40 sodium-induced colitis in mice. *Clin Exp Immunol* 107:353-358

41
42
43 Matsuo Y, Azuma YT, Kuwamura M, Kuramoto N, Nishiyama K, Yoshida N,
44
45
46 Ikeda Y, Fujimoto Y, Nakajima H, Takeuchi T (2015) Interleukin 19
47
48
49 reduces inflammation in chemically induced experimental colitis. *Int*
50
51
52 *Immunopharmacol* 29:468-475

53
54
55 Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G,
56
57
58 Caruso R, Tersigni R, Alessandrini L, Biancone L, Naccari GC,
59
60

1
2 MacDonald TT, Pallone F (2005) Interleukin-21 enhances T-helper cell
3
4
5 type I signaling and interferon-gamma production in Crohn's disease.
6
7
8 Gastroenterology 128:687-694
9

10
11 Naito Y, Takagi T, Handa O, Ishikawa T, Nakagawa S, Yamaguchi T, Yoshida
12
13
14 N, Minami M, Kita M, Imanishi J, Yoshikawa T (2003) Enhanced
15
16
17 intestinal inflammation induced by dextran sulfate sodium in tumor
18
19
20 necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 18:560-569
21

22
23 Naito Y, Takagi T, Uchiyama K, Kuroda M, Kokura S, Ichikawa H,
24
25
26 Yanagisawa R, Inoue K, Takano H, Satoh M, Yoshida N, Okanoue T,
27
28
29 Yoshikawa T (2004) Reduced intestinal inflammation induced by dextran
30
31
32 sodium sulfate in interleukin-6-deficient mice. Int J Mol Med 14:191-196
33

34
35 Sabat R, Wallace E, Endesfelder S, Wolk K (2007) IL-19 and IL-20: two novel
36
37
38 cytokines with importance in inflammatory diseases. Expert Opin Ther
39
40
41 Targets 11:601-612
42

43
44 Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA (2001) IL-1 beta -converting
45
46
47 enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA
48
49
50 98:13249-13254
51

52
53 Sitkauskiene B, Johansson AK, Sergejeva S, Lundin S, Sjöstrand M, Lötvall J
54
55
56 (2004) Regulation of bone marrow and airway CD34+ eosinophils by
57
58
59 interleukin-5. Am J respire Cell Mol Biol 30:367-378
60
61

1
2 Tanaka J, Saga K, Kido M, Nishiura H, Akamatsu T, Chiba T, Watanabe N
3
4
5 (2010) Proinflammatory Th2 cytokines induce production of thymic
6
7 stromal lymphopoietin in human colonic epithelial cells. *Dig Dis Sci*
8
9
10
11 55:1896-1904
12

13
14 Tong M, Li X, Wegener Parfrey L, Roth B, Ippoliti A, Wei B, Borneman J,
15
16 McGovern DP, Frank DN, Li E, Horvath S, Knight R, Braun J (2013) A
17
18 modular organization of the human intestinal mucosal microbiota and its
19
20
21
22 association with inflammatory bowel disease. *PLoS One* 8:e80702
23
24

25
26 Zhu J, Wang Y, Yang F, Sang L, Zhai J, Li S, Li Y, Wang D, Lu C, Sun X
27
28 (2015) IL-33 alleviates DSS-induced chronic colitis in C57BL/6 mice
29
30
31
32 colon lamina propria by suppressing Th17 cell response as well as Th1
33
34
35 cell response. *Int Immunopharmacol* 29:846-853
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 **Fig. 1.** Increased susceptibility of IL-19-KO mice to oxazolone-induced
3
4 colitis. (A) The percent weight loss of WT (n = 15) and IL-19-KO (n = 17)
5
6 mice was monitored daily. **P* < 0.05 compared with oxazolone-WT. (B)
7
8 Expression of *IL-19* mRNA in the distal colon of WT mice (n = 5) on day 2
9
10 post-oxazolone administration. **P* < 0.05 compared with 0 day. (C)
11
12 Histological evaluation in WT (n = 4) and IL-19-KO (n = 7) mice on day 2
13
14 post-oxazolone administration. Representative sections are shown. Scale bar,
15
16 100 μm. Histological scores were determined. **P* < 0.05 compared with WT.
17
18
19
20
21
22
23
24
25
26
27

28 **Fig. 2.** The transport of inflammatory cells into the colon, and IgE and
29
30 eosinophil level. (A) MPO activity in WT (n = 3) and IL-19-KO (n = 8) mice
31
32 on day 2 post-oxazolone administration. (B) Neutrophil and macrophage
33
34 infiltrations in WT (n = 4) and IL-19-KO (n = 4) mice on day 2 post-oxazolone
35
36 administration. Gr-1 and F4/80 immunofluorescence staining of representative
37
38 sections are shown. Scale bar, 10 μm. Each positive cell was enumerated. (C)
39
40 serum IgE levels, (D) serum eosinophils levels and eosinophils infiltrations in
41
42 WT (n = 4) and IL-19-KO (n = 7) mice on day 2 post-oxazolone
43
44 administration. Representative sections are shown. Scale bar, 20 μm. **P* <
45
46 0.05 compared with WT.
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 **Fig. 3.** Altered levels of cytokines. Cytokine expressions in WT (n = 7) and
3
4 IL-19-KO (n = 8) mice on day 2 post-oxazolone administration. The
5
6 expression levels of the indicated mRNAs were examined by quantitative
7
8 real-time PCR. * $P < 0.05$ compared with WT.
9
10

11
12
13
14
15
16 **Fig. 4.** Cytokine productions in (A) CD4⁺ T-cells and (B) cells by negative
17
18 selection with CD4⁺ from lymph node. Cytokine production in WT (n = 4) and
19
20 IL-19-KO (n = 7) mice on day 2 post-oxazolone administration. * $P < 0.05$,
21
22
23 ** $P < 0.01$ compared with WT.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1




Figure 2




Figure 3




Figure 4

